A detailed history of Bank Of America Corp transactions in Myriad Genetics Inc stock. As of the latest transaction made, Bank Of America Corp holds 2,705,635 shares of MYGN stock, worth $74.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,705,635
Previous 2,644,762 2.3%
Holding current value
$74.8 Million
Previous $56.4 Million 17.37%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$17.98 - $25.47 $1.09 Million - $1.55 Million
60,873 Added 2.3%
2,705,635 $66.2 Million
Q1 2024

May 15, 2024

SELL
$17.59 - $23.59 $6 Million - $8.05 Million
-341,135 Reduced 11.42%
2,644,762 $56.4 Million
Q4 2023

Feb 14, 2024

BUY
$13.91 - $21.32 $209,707 - $321,420
15,076 Added 0.51%
2,985,897 $57.2 Million
Q2 2023

Aug 14, 2023

SELL
$17.56 - $23.76 $8.12 Million - $11 Million
-462,148 Reduced 13.46%
2,970,821 $68.9 Million
Q1 2023

May 12, 2023

BUY
$15.26 - $23.75 $12 Million - $18.6 Million
783,718 Added 29.58%
3,432,969 $79.7 Million
Q4 2022

Feb 10, 2023

SELL
$14.51 - $20.99 $2.97 Million - $4.3 Million
-204,652 Reduced 7.17%
2,649,251 $38.4 Million
Q3 2022

Nov 14, 2022

BUY
$18.21 - $27.88 $2.08 Million - $3.19 Million
114,481 Added 4.18%
2,853,903 $54.5 Million
Q2 2022

Aug 12, 2022

SELL
$16.45 - $25.88 $325,413 - $511,958
-19,782 Reduced 0.72%
2,739,422 $49.8 Million
Q1 2022

May 16, 2022

BUY
$22.67 - $28.01 $6.12 Million - $7.56 Million
269,887 Added 10.84%
2,759,204 $69.5 Million
Q4 2021

Feb 08, 2022

SELL
$24.13 - $32.63 $2.36 Million - $3.19 Million
-97,808 Reduced 3.78%
2,489,317 $68.7 Million
Q3 2021

Nov 15, 2021

BUY
$29.97 - $36.66 $3.08 Million - $3.76 Million
102,611 Added 4.13%
2,587,125 $83.5 Million
Q2 2021

Sep 13, 2021

BUY
$25.39 - $32.61 $63.1 Million - $81 Million
2,484,514 New
2,484,514 $76 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $2.23B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.